Document Detail

Atorvastatin increases exercise leg blood flow in healthy adults.
MedLine Citation:
PMID:  22018642     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We sought to examine the effect of atorvastatin therapy on exercise leg blood flow in healthy middle-aged and older-men and women.
BACKGROUND: The vasodilatory response to exercise decreases in humans with aging and disease and this reduction may contribute to reduced exercise capacity.
METHODS: We used a double-blind, randomly assigned, placebo-controlled protocol to assess the effect of atorvastatin treatment on exercising leg hemodynamics. We measured femoral artery blood flow (FBF) using Doppler ultrasound and calculated femoral vascular conductance (FVC) from brachial mean arterial pressure (MAP) before and during single knee-extensor exercise in healthy adults (ages 40-71) before (PRE) and after (POST) 6 months of 80 mg atorvastatin (A: 14 men, 16 women) or placebo (P: 14 men, 22 women) treatment. FBF and FVC were normalized to exercise power output and estimated quadriceps muscle mass.
RESULTS: Atorvastatin reduced LDL cholesterol by approximately 50%, but not in the placebo group (p < 0.01). Atorvastatin also increased exercise FBF from 44.2 ± 19.0 to 51.4 ± 22.0 mL/min/W/kg muscle whereas FBF in the placebo group was unchanged (40.1 ± 16.0 vs. 39.5 ± 16.1) (p < 0.01). FVC also increased with atorvastatin from 0.5 ± 0.2 to 0.6 ± 0.2 mL/min/mmHg/W/kg muscle, but not in the placebo subjects (P: 0.4 ± 0.2 vs. 0.4 ± 0.2) (p < 0.01).
CONCLUSIONS: High-dose atorvastatin augments exercising leg hyperemia. Statins may mitigate reductions in the exercise vasodilatory response in humans that are associated with aging and disease.
Beth A Parker; Jeffrey A Capizzi; Amanda L Augeri; Adam S Grimaldi; C Michael White; Paul D Thompson
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2011-10-04
Journal Detail:
Title:  Atherosclerosis     Volume:  219     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-29     Completed Date:  2012-04-05     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  768-73     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Blood Flow Velocity / drug effects
Double-Blind Method
Drug Administration Schedule
Femoral Artery / drug effects*,  physiopathology,  ultrasonography
Heptanoic Acids / administration & dosage*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Hyperemia / physiopathology
Lipids / blood
Lower Extremity / blood supply*
Middle Aged
Muscle Contraction
Pyrroles / administration & dosage*
Regional Blood Flow / drug effects
Time Factors
Ultrasonography, Doppler
Vasodilation / drug effects*
Grant Support
1R01HL098085-01/HL/NHLBI NIH HHS; 5R01HL081893-04/HL/NHLBI NIH HHS; R01 HL081893/HL/NHLBI NIH HHS; R01 HL081893-04/HL/NHLBI NIH HHS; R01 HL098085-02/HL/NHLBI NIH HHS
Reg. No./Substance:
0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Placebos; 0/Pyrroles; A0JWA85V8F/atorvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Eicosapentaenoic acid administration attenuates the pro-inflammatory properties of VLDL by decreasin...
Next Document:  Ankle brachial pressure index but not brachial-ankle pulse wave velocity is a strong predictor of sy...